Portland, Canada

Clarke Slemon

This inventor holds 5 USPTO granted patents and 1 published patent application. Top assignees: American Diagnostica, Inc., Quebepharma Recherche, Inc., Other. Active years: 1996-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Clarke Slemon. Retrieved from https://idiyas.com/inventor/clarke-slemon-w95pv2de

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 

% Patents Active = 60.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Ontario, CA (1996)
  • Montreal, CA (2004)
  • Portland, CA (2006 - 2010)

Company Filing History:


Years Active: 1996-2010

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Inventor Clarke Slemon

Introduction

Clarke Slemon is a notable inventor based in Portland, CA. He has made significant contributions to the field of medical research, particularly in the development of methods and compounds that address various health conditions. With a total of 5 patents to his name, Slemon's work has the potential to impact the treatment and management of several diseases.

Latest Patents

Slemon's latest patents include innovative methods for screening compounds that modulate TAFIa activity. These methods provide a way to identify compounds with aspirin-related activity, which can be used to treat, prevent, or manage conditions such as pain, fever, colon cancer, pancreatic cancer, and various inflammatory diseases. Additionally, he has developed methods for evaluating test compounds for TAFI inhibitory activity, comparing them to aspirin and its derivatives. His work also includes methods for treating hemorrhagic or thrombotic diseases using high doses of aspirin or its derivatives, along with factors that promote TAFIa activity to mitigate adverse side effects.

Another significant patent involves the regulation of gene expression through methylated nucleotide sequences. This method focuses on the urokinase type plasminogen activator (uPA) gene, utilizing methylated antisense oligonucleotides to promote methylation of target nucleotide sequences in mammalian cells. These advancements highlight Slemon's commitment to addressing complex medical challenges through innovative solutions.

Career Highlights

Throughout his career, Clarke Slemon has worked with various organizations, including American Diagnostica, Inc. His experience in the industry has allowed him to develop and refine his inventions, contributing to advancements in medical research and treatment methodologies.

Collaborations

Slemon has collaborated with notable individuals in his field, including Jean Vaugeois and Seong Soo A An. These partnerships have likely enhanced the scope and impact of his research, fostering innovation through shared expertise.

Conclusion

Clarke Slemon's contributions to the field of medical research through his patents and collaborations demonstrate his dedication to improving health outcomes. His innovative methods and compounds have the potential to significantly influence the treatment of various diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…